CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells - PubMed (original) (raw)
. 2003 Jun 1;63(11):2836-43.
Affiliations
- PMID: 12782589
CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells
Réjean Lapointe et al. Cancer Res. 2003.
Abstract
Although they are considered as antigen-presenting cells, the role of antigen-unspecific B lymphocytes in antigen presentation and T-lymphocyte stimulation remains controversial. In this paper, we tested the capacity of normal human peripheral activated B cells to stimulate T cells using melanoma antigens or melanoma cell lysates. B lymphocytes activated through CD40 ligation and then pulsed with tumor antigens efficiently processed and presented MHC class II-restricted peptides to specific CD4(+) T-cell clones. This suggests that CD40-activated B cells have the functional and molecular competence to present MHC class II epitopes when pulsed with exogenous antigens, thereby making them a relevant source of antigen-presenting cells to generate T cells. To test this hypothesis, CD40-activated B cells were pulsed with a lysate prepared from melanoma cells and used to stimulate peripheral autologous T cells. Interestingly, T cells specific to melanoma antigens were generated. Additional analysis of these T-cell clones revealed that they recognized MHC class II-restricted epitopes from tyrosinase, a known melanoma tumor antigen. The efficient antigen presentation by antigen-unspecific activated B cells was correlated with a down-regulation in the expression of HLA-DO, a B cell-specific protein known to interfere with HLA-DM function. Because HLA-DM is important in MHC class II peptide loading, the observed decrease in HLA-DO may partially explain the enhanced antigen presentation after B-cell activation. Results globally suggest that when they are properly activated, antigen-unspecific B-lymphocytes can present exogenous antigens by MHC class II molecules and stimulate peripheral antigen-specific T cells. Antigen presentation by activated B cells could be exploited for immunotherapy by allowing the in vitro generation of T cells specific against antigens expressed by tumors or viruses.
Comment in
- Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43.
von Bergwelt-Baildon M, Schultze JL, Maecker B, Menezes I, Nadler LM. von Bergwelt-Baildon M, et al. Cancer Res. 2004 Jun 1;64(11):4055-6; author reply 4056-7. doi: 10.1158/0008-5472.CAN-03-3606. Cancer Res. 2004. PMID: 15173021 No abstract available.
Similar articles
- Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H, Nagato T, Takahara M, Sato K, Kimura S, Aoki N, Azumi M, Tateno M, Harabuchi Y, Celis E. Kobayashi H, et al. Cancer Res. 2008 Feb 1;68(3):901-8. doi: 10.1158/0008-5472.CAN-07-3212. Cancer Res. 2008. PMID: 18245493 - NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM. Zarour HM, et al. Cancer Res. 2002 Jan 1;62(1):213-8. Cancer Res. 2002. PMID: 11782380 - Antigen-presenting cells and the selection of immunodominant epitopes.
Blum JS, Ma C, Kovats S. Blum JS, et al. Crit Rev Immunol. 1997;17(5-6):411-7. Crit Rev Immunol. 1997. PMID: 9419428 Review. - [MHC tetramers: tracking specific immunity].
Kosor E, Gagro A, Drazenović V, Kuzman I, Jeren T, Rakusić S, Rabatić S, Markotić A, Gotovac K, Sabioncello A, Cecuk E, Kerhin-Brkljacić V, Gjenero-Margan I, Kaić B, Mlinarić-Galinović G, Kastelan A, Dekaris D. Kosor E, et al. Acta Med Croatica. 2003;57(4):255-9. Acta Med Croatica. 2003. PMID: 14639858 Review. Croatian.
Cited by
- MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4+ T cells in vivo.
Guy TV, Terry AM, McGuire HM, Shklovskaya E, Fazekas de St Groth B. Guy TV, et al. Oncoimmunology. 2023 Dec 10;13(1):2290799. doi: 10.1080/2162402X.2023.2290799. eCollection 2024. Oncoimmunology. 2023. PMID: 38125720 Free PMC article. - Multifunctional magnetic nanoparticles elicit anti-tumor immunity in a mouse melanoma model.
Lafuente-Gómez N, de Lázaro I, Dhanjani M, García-Soriano D, Sobral MC, Salas G, Mooney DJ, Somoza Á. Lafuente-Gómez N, et al. Mater Today Bio. 2023 Sep 24;23:100817. doi: 10.1016/j.mtbio.2023.100817. eCollection 2023 Dec. Mater Today Bio. 2023. PMID: 37822453 Free PMC article. - Cancer Vaccines: From the State of the Art to the Most Promising Frontiers in the Treatment of Colorectal Cancer.
Martinis E, Ricci C, Trevisan C, Tomadini G, Tonon S. Martinis E, et al. Pharmaceutics. 2023 Jul 17;15(7):1969. doi: 10.3390/pharmaceutics15071969. Pharmaceutics. 2023. PMID: 37514155 Free PMC article. Review. - Lipid-Polymer Hybrid Nanoparticles Utilize B Cells and Dendritic Cells to Elicit Distinct Antigen-Specific CD4+ and CD8+ T Cell Responses.
Zhang MH, Scotland BL, Jiao Y, Slaby EM, Truong N, Cottingham AL, Stephanie G, Szeto GL, Pearson RM. Zhang MH, et al. ACS Appl Bio Mater. 2024 Aug 19;7(8):4818-4830. doi: 10.1021/acsabm.3c00229. Epub 2023 May 23. ACS Appl Bio Mater. 2024. PMID: 37219857 Review. - Immortalized B Cells Transfected with mRNA of Antigen Fused to MITD (IBMAM): An Effective Tool for Antigen-Specific T-Cell Expansion and TCR Validation.
Wang Z, Zhang T, Anderson A, Lee V, Szymura S, Dong Z, Kuang B, Oh E, Liu J, Neelapu SS, Kwak L, Cha SC. Wang Z, et al. Biomedicines. 2023 Mar 6;11(3):796. doi: 10.3390/biomedicines11030796. Biomedicines. 2023. PMID: 36979775 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials